UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

Clinical pharmacokinetics, 2015-07, Vol.54 (7), p.677-690

2015

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C

Clinical pharmacokinetics, 2016-11, Vol.55 (11), p.1337-1351

2016

Volltextzugriff (PDF)

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin

Clinical pharmacology and therapeutics, 2018-12, Vol.104 (6), p.1182-1190

2018

Volltextzugriff (PDF)

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

The Lancet (British edition), 2012-06, Vol.379 (9835), p.2439-2448

2012

Volltextzugriff (PDF)

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

The Lancet (British edition), 2012-06, Vol.379 (9835), p.2429-2438

2012

Volltextzugriff (PDF)

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

Clinical pharmacokinetics, 2011-04, Vol.50 (4), p.229-244

2011

Volltextzugriff (PDF)

Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir

Clinical pharmacokinetics, 2018-11, Vol.57 (11), p.1369-1383

2018

Volltextzugriff (PDF)

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

Clinical pharmacokinetics, 2016-05, Vol.55 (5), p.605-613

2016

Volltextzugriff (PDF)

Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial

The Journal of infectious diseases, 2010-03, Vol.201 (6), p.814-822

2010

Volltextzugriff (PDF)

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel

PloS one, 2011-10, Vol.6 (10), p.e25974

2011

Volltextzugriff (PDF)

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate versus efavirenz/ emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

AIDS (London), 2011-03, Vol.25 (6), p.F7-F12

2011

Volltextzugriff (PDF)

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

Journal of acquired immune deficiency syndromes (1999), 2006-09, Vol.43 (1), p.1-5

2006

Volltextzugriff (PDF)

A comprehensive evaluation in clinic and physiologically‐based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450–mediated drug–drug interaction potential for pomotrelvir

CPT: pharmacometrics and systems pharmacology, 2023-10, Vol.12 (10), p.1553-1564

2023

Volltextzugriff (PDF)

Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens

Journal of acquired immune deficiency syndromes (1999), 2005-08, Vol.39 (4), p.406-411

2005

Volltextzugriff (PDF)

Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological Effects

Antimicrobial Agents and Chemotherapy, 2008-09, Vol.52 (9), p.3144-3160

2008

Volltextzugriff (PDF)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib

Clinical pharmacokinetics, 2016-01, Vol.55 (1), p.33-45

2016

Volltextzugriff (PDF)

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

Antimicrobial Agents and Chemotherapy, 2001-10, Vol.45 (10), p.2733-2739

2001

Volltextzugriff (PDF)

Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals

Journal of acquired immune deficiency syndromes (1999), 2018-08, Vol.78 (4), p.465-472

2018

Volltextzugriff (PDF)

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine

Clinical pharmacology and therapeutics, 2018-12, Vol.104 (6), p.1191-1198

2018

Volltextzugriff (PDF)

Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function

Journal of acquired immune deficiency syndromes (1999), 2012-09, Vol.61 (1), p.32-40

2012

Volltextzugriff (PDF)

Characterization of Pharmacokinetics, Biotransformation and Elimination of Pomotrelvir Orally Administered in Healthy Male Adults Using Two [ 14 C]-Labeled Microtracers with Separate Labeling Positions

Drug metabolism and disposition, 2023-12, Vol.51 (12), p.1607-1614

2023

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment

Antimicrobial agents and chemotherapy, 2016-09, Vol.60 (9), p.5135-5140

2016

Volltextzugriff (PDF)

Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Volltextzugriff (PDF)

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies

British journal of clinical pharmacology, 2022-07, Vol.88 (7), p.3211-3221

2022

Volltextzugriff (PDF)

Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment

Clinical pharmacokinetics, 2006-01, Vol.45 (11), p.1115-1124

2006

Volltextzugriff (PDF)

1 – 25 von 149

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(101)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(148)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate versus efavirenz/ emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

A comprehensive evaluation in clinic and physiologically‐based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450–mediated drug–drug interaction potential for pomotrelvir

Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens

Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological Effects

Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine

Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function

Characterization of Pharmacokinetics, Biotransformation and Elimination of Pomotrelvir Orally Administered in Healthy Male Adults Using Two [ 14 C]-Labeled Microtracers with Separate Labeling Positions

Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment

Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies

Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment

Suchergebnisse filtern